Foghorn Therapeutics FHTX
NASDAQ FHTX
$4.90 +0.03 (+0.62%)
As of: Sep 4, 2026 · 12:47 PM EDT

Foghorn Therapeutics (FHTX) Non Operating Interest Expenses (2019 - 2021)

Analysis

Foghorn Therapeutics (FHTX) Non Operating Interest Expenses (2019 - 2021) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Vertex Pharmaceuticals 139.76 Bn 131.91 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.72 Bn 77.72 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.56 Bn 58.38 Bn 1.37 Bn -1.00 Mn
4 Moderna 57.87 Bn 52.73 Bn 52.00 Mn -
5 Revolution Medicines 44.06 Bn 44.06 Bn - 23.78 Mn
6 BeOne Medicines 40.08 Bn 34.98 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.50 Bn 32.20 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.54 Bn 27.70 Bn - 93.62 Mn
9 Insmed 27.49 Bn 26.33 Bn 358.27 Mn 20.27 Mn
10 Foghorn Therapeutics 345.02 Mn 276.94 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 426,000.00
Sep 30, 2021 499,000.00
Jun 30, 2021 495,000.00
Mar 31, 2021 486,000.00
Dec 31, 2020 321,000.00
Sep 30, 2020 202,000.00
Jun 30, 2020 198,000.00
Mar 31, 2020 258,000.00
Dec 31, 2019 178,000.00
Sep 30, 2019 113,000.00